Mitral Remodeling Index: A Novel Composite Measure the Effect of ARNI Alone Versus ARNI Combined With SGLT2 Inhibitors on Functional Mitral Regurgitation Remodeling.
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Observational
SUMMARY
This study aimed to compare the effects of ARNI monotherapy versus combined ARNI and SGLT2 inhibitor therapy on Mitral Remodeling Index (MRIx) and Functional mitral regurgitation (FMR) remodeling in patients with heart failure with reduced ejection fraction (HFrEF).
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
View:
• age ≥18 years;
• left ventricular ejection fraction (LVEF) \<50%;
• Presence of functional mitral regurgitation (mild, moderate, or severe) on transthoracic echocardiography; and
• stable sinus rhythm or controlled atrial fibrillation.
Locations
Other Locations
Saudi Arabia
Madinah Cardiac Center
RECRUITING
Madinah
Contact Information
Primary
Rehab H Werida, Ass. Prof.
rehabwrieda@pharm.dmu.edu.eg
01005359968
Backup
Eman Elshaikh, Ass. Prof.
eelsheikh@kfu.edu.sa
Time Frame
Start Date: 2025-12-25
Estimated Completion Date: 2026-03-01
Participants
Target number of participants: 180
Treatments
ARNI Monotherapy Group:
Patients receiving sacubitril/valsartan without concomitant SGLT2 inhibitor therapy.
Combination Therapy Group:
Patients receiving sacubitril/valsartan in combination with an SGLT2 inhibitor (empagliflozin 10 mg daily).
Related Therapeutic Areas
Sponsors
Leads: Rehab Werida
Collaborators: Madinah Cardiac Center in Madinah, KSA., Tanta University